Implementation of Clinical Cytochrome P450 3A Genotyping for Tacrolimus Dosing in a Large Kidney Transplant Program.

doi:10.1002/jcph.2249

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Implementation of Clinical Cytochrome P450 3A Genotyping for Tacrolimus Dosing in a Large Kidney Transplant Program.

Journal of clinical pharmacology - 1 Aug 2023

Tillman Emma, Nikirk Miley G, Chen Jeanne, Skaar Todd C, Shugg Tyler, Maddatu Judith P, Sharfuddin Asif A, Eadon Michael T

Abstract excerpt

Tacrolimus is a calcineurin inhibitor with a narrow therapeutic range and is metabolized by cytochrome P450 (CYP) isoenzymes CYP3A4 and CYP3A5. The Clinical Pharmacogenetic Implementation Consortium published evidence-based guidelines for CYP3A5 normal/intermediate metabolizers prescribed tacrolimus, yet few transplant centers have implemented routine testing. The objective of this study was to implement...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Genotype
Share to Immunosuppressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney Diseases

Share to Kidney Transplantation

Share to Polymorphism, Single Nucleotide

Share to Renal Transplantation Outcomes and Treatments

Share to Tacrolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 37042314
DOI: 10.1002/jcph.2249
PMCID: PMC10478012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.